National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 59940-59941 [2012-24003]
Download as PDF
<![CDATA[
59940
Federal Register / Vol. 77, No. 190 / Monday, October 1, 2012 / Notices
Contact Person: Susana Mendez, Ph.D.,
DVM, Scientific Review Officer, Scientific
Review Program, DEA/NIAID/NIH/DHHS,
6700B Rockledge Drive, MSC–7616,
Bethesda, MD 20892–7616, 301–496–2550,
mendezs@niaid.nih.gov.
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 25, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: September 24, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–24006 Filed 9–28–12; 8:45 am]
[FR Doc. 2012–24005 Filed 9–28–12; 8:45 am]
BILLING CODE 4140–01–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Allergy, Immunology,
and Transplantation Research Committee.
Date: October 17, 2012.
Time: 10 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Room #3136, Bethesda, MD
20817, (Telephone Conference Call).
Contact Person: Zhuqing Li, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–402–9523,
zhuqing.li@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Targeting Inflammation and
Immune Activations in HIV Disease.
Date: October 22–23, 2012.
Time: 11 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817,
(Telephone Conference Call).
Contact Person: Quirijn Vos, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–496–2550,
qvos@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasisn Panel; Partnerships for
Biodefense—Bacterial Therapeutics (2).
Date: October 3, 2012.
Time: 11 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817
(Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institutes of Health/NIAID, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, 301–594–1009,
fdesilva@niaid.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Partnerships for
Development of Vaccine Technologies.
Date: October 24–25, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 24, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
mstockstill on DSK4VPTVN1PROD with NOTICES
[FR Doc. 2012–24004 Filed 9–28–12; 8:45 am]
VerDate Mar<15>2010
16:48 Sep 28, 2012
Jkt 226001
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Program Project on
Pancreatitis.
Date: November 12, 2012.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 758, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–7637, davilabloomm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special, Emphasis Panel; KUH–K–T Member
Conflict Telephone SEP.
Date: November 14, 2012.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\01OCN1.SGM
01OCN1
Federal Register / Vol. 77, No. 190 / Monday, October 1, 2012 / Notices
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Dated: September 24, 2012.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Name of Committee: National Institute of
Nursing Research Initial Review Group.
Date: October 18, 2012.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Weiqun Li, MD, Scientific
Review Officer, National Institute of Nursing
Research, National Institutes of Health, 6701
Democracy Blvd., Ste. 710, Bethesda, MD
20892, (301) 594–5966, wli@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.361, Nursing Research,
National Institutes of Health, HHS)
[FR Doc. 2012–24003 Filed 9–28–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
59941
Dated: September 25, 2012.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–24001 Filed 9–28–12; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Terahertz Scanning Systems
for Cancer Pathology
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
ACTION:
Notice.
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of a worldwide
exclusive evaluation option license, to
practice the inventions embodied in:
SUMMARY:
HHS REF. NO. E–243–2010/0 ‘‘TETRAHERTZ SPATIAL LIGHT MODULATOR FOR COMPUTER-CONTROLLED ADAPTIVE NEAR
FIELD IMAGING OF BIOLOGICAL SYSTEMS’’
Territory
Filing date
61/425,007 ...............................................................
PCT/US2011/65734 .................................................
mstockstill on DSK4VPTVN1PROD with NOTICES
Patent application No.
US ..................................
Int’l ..................................
December 20, 2010 ................................................
December 19, 2011 ................................................
to Transformatix Technologies, Inc., a
company incorporated under the laws of
the State of California having its
headquarters in Davis, California. The
United States of America is the assignee
of the rights of the above inventions.
The contemplated exclusive license may
be granted in a field of use limited to
terahertz scanning systems for cancer
pathology. Upon the expiration or
termination of the exclusive evaluation
option license, Transformatix will have
the right to execute an exclusive patent
commercialization license which will
supersede and replace the exclusive
evaluation option license with no
greater field of use and territory than
granted in the evaluation license.
Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before October 16, 2012 will be
considered.
DATES:
Requests for a copy of the
patent application, inquiries, comments
ADDRESSES:
VerDate Mar<15>2010
16:48 Sep 28, 2012
Jkt 226001
and other materials relating to the
contemplated license should be directed
to: Michael A. Shmilovich, Esq., CLP,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5019; Facsimile: (301) 402–0220; Email:
shmilovm@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published by the United States Patent
and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The patent
applications (including any patents
issuing therefrom or claiming priority
thereto) intended for licensure describe
and claim a terahertz (THz) imaging
system that may overcome the
limitations of existing systems by using
the near-field effect at THz frequencies
to provide micron-scale spatial
resolution. Additionally, the THz
imaging system describes a sensor head
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Status
Expired.
Pending.
geometry that eliminates the
requirement to mechanically scan
samples, and also allows automatic
adjustment of image resolution and
transmitted power. The claimed system
has no moving components and is
therefore potentially suitable for
medical applications such as cancer
diagnosis of living subjects in hospital
settings. In one application, such as
‘‘one-cut’’ surgery, the compact sensor
head of the system may have the
capability of distinguishing healthy
cells from cancerous cells with micronscale spatial resolution by identifying a
skin cancer margin without the need for
laboratory work or the possibility of
additional surgery.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within fifteen (15) days from the date of
this published notice, NIH receives
written evidence and argument that
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 77, Number 190 (Monday, October 1, 2012)]
[Notices]
[Pages 59940-59941]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-24003]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Program Project on
Pancreatitis.
Date: November 12, 2012.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, One Democracy Plaza, 6701
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Maria E. Davila-Bloom, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 758, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-7637, davila-bloomm@extra.niddk.nih.gov.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special, Emphasis Panel; KUH-K-T Member Conflict
Telephone SEP.
Date: November 14, 2012.
Time: 10:30 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 59941]]
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Xiaodu Guo, MD, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 761, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-4719, guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: September 24, 2012.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-24003 Filed 9-28-12; 8:45 am]
BILLING CODE 4140-01-P
